Loading...
•
Dec 31, 2021
CervoMed Q4 2021 Earnings Report
Diffusion Pharmaceuticals reported its financial results for 2021 and provided a business update.
Key Takeaways
Diffusion Pharmaceuticals reported cash and cash equivalents of $37.3 million as of December 31, 2021. The company is focused on advancing its lead product candidate, TSC, for hypoxic solid tumors.
Altitude Trial dosing expected to be completed in 2Q2022; mid-2022 for ILD-DLCO Trial.
Phase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start.
Cash and cash equivalents totaled $37.3M as of year-end 2021.
Cash is expected to fund operations through 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...